Journal of Crohns & Colitis

Article	Citations
P750 Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes: A Real-World Effectiveness Analyses in a National U.S. Cohort of U.S. Military Veterans with Inflammatory Bowel Disease	262
P139 Inflammatory bowel disease and impairment of working life	259
P222 Chronic pain is common in Paediatric Inflammatory Bowel Disease and impacts quality of life	229
OP32 The gut virome-colonizing Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo	225
P709 Endoscopic healing and clinical remission after administration of adalimumab to patients with Crohn’s disease of the small intestine	114
P833 Cervical cancer risk in newly diagnosed ulcerative colitis: a nationwide population-based study	106
P501 Safety of peri-operative biologics in patients with IBD undergoing resective bowel surgery: experiences of a single center cohort	98
P905 Predictive pharmacogenetic risk of pancreatitis in Inflammatory Bowel Disease patients treated with thiopurines: a case-control study from the ENEIDA registry	96
P127 Inflammatory Bowel Disease-associated colorectal cancers: retrospective cohort study from a tertiary centre surveillance programme over 10 years	95
P113 Protein fingerprint biomarkers of collagen remodeling can evaluate fibrogenesis in an in vitro colonic scar-in-a-jar model	71
P149 Novel capillary blood point-of-care test for adalimumab and infliximab trough levels: Effects of abnormal blood conditions on the test result	69
P310 Smoking is not an independent risk factor for surgery in patients with Crohn’s Disease on biologic therapy	58
P294 Assessment of Fatigue and Associated Factors in Patients with Inflammatory Bowel Disease: A Questionnaire-based Study	56
P308 A new endoscopic scoring system corresponding to histological healing using linked color imaging in ulcerative colitis: SOUL study	55
P358 Long-term clinical outcomes of intestinal Behçet’s disease: a 30-year cohort study at a tertiary hospital in South Korea	55
P089 Colonic explant lactate concentration and inflammatory protein secretion in ulcerative colitis	54
P324 Long-term impact of the COVID-19 pandemic on Inflammatory Bowel Disease healthcare utilization: A two-year nationwide update	54
P212 The Impact of Crohn’s Disease in Patients with Colorectal Cancer: A Danish Nationwide Cohort Study, 2009-2019	53
P0435 Comparative analysis between capsule endoscopy and ileocolonoscopy for activity detection in ileal Crohn’s disease. Preliminary results from the CAPITER study, a multicenter study from the Young	52
Corrigendum to: ECCO CONFER Investigators, Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series	52
P0279 Assessing patient-reported health status in moderate-to-severe Crohn’s Disease and Ulcerative Colitis: Results from the communicating needs and features of IBD experiences (CONFIDE) survey	52
P551 Platelet-to-lymphocyte ratio index for non-invasive assessment of endoscopic activity in small bowel Crohn’s disease: application and prospective validation.	51
P0893 Angiopoietin-like Protein 8 (ANGPTL8) in Inflammatory Bowel Disease and Its Response to Anti-TNFα Therapy; A Prospective Multi Center Study	50
P748 Pharmacokinetics, relative bioavailability, and dose proportionality of a tablet formulation of the sphingosine 1-phosphate-1 receptor modulator VTX002 (formerly OPL-002)	50
P0166 Changes in bone mineral density in young patients with inflammatory bowel diseases	48

P1288 The Association of Long-term Night Shift Work and Related Circulating Proteins with Inflammatory Bowel Disease: A Prospective Cohort and Multi-omics Study	48
P1244 Differential impact of appendectomy with appendiceal inflammation versus no inflammation on inflammatory bowel disease risk in a population-based cohort	48
P0391 The impact of point of care ultrasound on time to initiating advanced therapy in IBD (GUIDE-IBD): A randomised controlled trial	46
P1252 Prevalence, Incidence and Mortality of Pediatric Inflammatory Bowel Disease in Catalonia	46
P0406 Complications after ileal pouch-anal anastomosis in patients with Ulcerative Colitis and primary sclerosing cholangitis	45
P0089 Infra-red microspectroscopy provides quantitative assessment of fibro-inflammation in Crohn’s disease strictures and predicts post-operative recurrence	45
P0381 Correlation Between Rectal Endoscopic and Histological Involvement and the Prevalence and Severity of Ano-Perineal Lesions in Inflammatory Bowel Disease	44
DOP022 Shared and Distinct Features of the Gut Microbiome in Immune-mediated Inflammatory Diseases: Initial Analysis from the INTEGRATE Cohort Study	44
P0483 Assessment of Disease Activity in Pediatric Inflammatory Bowel Disease Using Intestinal Ultrasound: A Comparative Diagnostic Analysis	43
P0346 Pouch Fistulas: Experience From a Tertiary Center	43
P0453 Intestinal Ultrasound Correlates with Patient-Reported IBD Disability in Ulcerative Colitis: A Step Towards Integrated Monitoring	43
P0292 CD8+ Cell Dominance in Immune Checkpoint Inhibitor-Induced Colitis and Its Heterogeneity Across Endoscopic Features	42
P0250 Circulating blood matrix metalloproteinase (MMP)-10 and 12 can accurately predict mucosal healing in Inflammatory Bowel Disease (IBD) in a multi-centred prospective longitudinal cohort study (20	42
Navigating Postoperative Management in Crohn’s Disease: Insights from the PORCSE Study	40
P0818 Addressing unmet needs in adult Inflammatory Bowel Disease care	40
P0742 Real-world efficacy and safety of Upadacitinib in IBD patients. Preliminary data from the Apulian Network for Inflammatory Bowel Disease (AN-IBD)	40
P0551 Diagnostic Accuracy of Low-Cost Blood Test Inflammatory Markers in Severe Ulcerative Colitis	40
P143 Efficacy of the oral tyrosine kinase 2 (TYK2) inhibitor TAK-279 in two preclinical mouse models of colitis	40
P0746 Impact of timing of prophylaxis therapy on post-operative endoscopic recurrence in a real-life cohort of patients whit Crohn’s disease	39
DOP053 Efficacy of appendectomy in inducing remission in moderate-to-severe ulcerative colitis: preliminary one year results of a multicentre prospective cohort study (COSTA)	38
P0003 Differential Effects of JAK Inhibitors on Epithelial-Immune Interaction in Inflammatory Bowel Disease	38
DOP79 Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort	38
Results of the Ninth Scientific Workshop of the European Crohn’s and Colitis Organisation (ECCO): Artificial Intelligence in medical management and precision medicine	37
Results of the Ninth Scientific Workshop of the European Crohn’s and Colitis Organisation (ECCO): artificial intelligence in IBD surgery—opportunities and limitations	37
Disruption of Epithelial Barrier Integrity via Altered GILZ/c-Rel/RACK1 Signaling in Inflammatory Bowel Disease	36
P1090 Exposure to an inflammatory prenatal environment and the risk of Inflammatory Bowel Disease in the offspring: a population-based cohort study	36
Decreased Levels of Atmospheric Pollution and Reduced Prevalence of Inflammatory Bowel Diseases in Europe	36
P228 Predictors of steroid therapy refractoriness in admitted Acute Severe Ulcerative Colitis patients	35
P081 The integration of transcriptomic and microbiomic data links several intestinal bacterial families with key biological functions in the development of postoperative recurrence in Crohn's disease	35
P360 Prevalence and risk factors for fatigue in patients with inflammatory bowel disease and endoscopic healing	34
P346 Assessing Brain Morphology in Functional Gastrointestinal and Inflammatory Bowel Disorders Using Functional Magnetic Resonance Imaging (fMRI)	34
P273 Defining the prognosis of children with Crohn Disease with the support of magnetic resonance enterography: a multi-center multi-reader study	34
P497 Malnutrition in inflammatory bowel disease: a correlation between clinical and nutritional parameters	33
P387 Short and long-term outcomes of surgery for inflammatory (uncomplicated) ileocecal Crohn’s disease: multicentric retrospective analysis of 211 patients	33
P732 Lack of concordance between patient-reported, physician-reported and objective criteria-based identification of suboptimal control in IBD patients: IBD PODCAST study results	33
P771 Comparing obstructive symptoms and dietary restrictions with Crohn's disease stricture severity	33
P929 Relation between Crohn’s disease phenotype and response to ustekinumab in Stockholm – the STOCUSTE study	32
P918 Can we rely on HLA to predict resistance to biological therapy in Inflammatory Bowel Disease patients?	32
P899 Inflammatory Bowel Disease Patients Show More Recognizable Digestive Symptoms of COVID-19: A Questionnaire Study	32
P1213 The role of stress in dietary choices and disease outcomes in Inflammatory Bowel Disease	31
P926 Improved standards of colonoscopy for Inflammatory Bowel Disease through implementation of key performance measures - A quality improvement initiative	31
P720 Exit interviews exploring Crohn’s disease patients’ experience of changes in their bowel urgency during the mirikizumab Phase 3 clinical trial in adult patients with moderate to severe Crohn dise	31
DOP057 Early serum and faecal cytokines predict clinical outcomes in Acute Severe Ulcerative Colitis: results from PREDICT-UC	31
Definitions, diagnosis, and management of postoperative recurrence in Crohn’s disease patients with permanent ileostomy—a systematic review and meta-analysis	31
P0486 Mesenteric and Anti-mesenteric Border Sub-regionalization Using MR Enterography: Advancing Fibrosis Evaluation in Crohn’s Disease	30
P083 JAK/STAT pathway and IL-6 activity in moderate to severe Ulcerative Colitis	30
P0206 Characteristics of Upper Gastrointestinal Involvement in Crohn’s Disease: A Greek multicenter study	30
P0405 The Influence of Psychological support in Patients with Ulcerative Colitis for Adherence to Drug Therapy	29
P0218 Acute Severe Ulcerative Colitis without systemic toxicity: a retrospective multicenter cohort study suggesting refining the definition of Acute Severe Ulcerative Colitis	29
P0545 The clinical characteristics of patients with Crohn’s disease and orofacial granulomatosis; high rates or perianal and oesophageal involvement	29

P0443 Long-term outcome of patients with Ulcerative Colitis after Ileal Pouch–Anal Anastomosis: the Latium NET study, preliminary data	28
P0304 An Inflammatory Bowel Disease clinic with integrated mental health screening results in more referrals and greater follow-up to the psychogastroenterology service	28
P0156 SIK2 selective inhibitors demonstrate dual anti-inflammatory and mucosal repair profiles in human ex vivo models of Ulcerative Colitis	28
DOP048 Multi-omics Profiling Reveals Shared and Distinct Plasma Predictors of Anti-TNF Resistance Across Crohn’s Disease Subtypes	28
DOP086 Latitude Gradient in Advanced IBD Therapy Prescribing in Australia, 2007-2025	28
P0069 Mucin RNA Isoform Expression and Its Association with Clinical Severity Scores and Barrier Gene Networks in Ulcerative Colitis	27
Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn’s Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial	27
DOP100 Combination treatment with adalimumab and partial enteral nutrition compared with adalimumab monotherapy in adults with active Crohn’s disease: The BIOPIC study	27
P365 Incidental terminal ileitis in asymptomatic patients. Is it Crohn’s disease?	27
P0158 Clostridium butyricum regulates T-helper 17 cells-related immune response in dextran sodium sulfate-induced colitis mice by targeting Toll-like receptor 2	27
Early intestinal ultrasound response to biologic and small molecule therapy is accurate to predict treat-to-target endoscopic outcomes in children with ulcerative colitis: results from the prospective	27
DOP026 Porphyromonas gingivalis secreted htpG disrupts TLR4/ PAPSS2-mediated mucin sulfation and aggravates ulcerative colitis	26
DOP115 Exophiala dermatitidis aggravates colitis through the Syk-CARD9 signaling pathway	26
DOP012 Promising effects of IMU-856, an orally available epigenetic modulator of barrier regeneration - biomarker findings from a Phase 1 clinical study	26
P694 Age is a strong of predictive risk factor for anti-TNF therapy related adverse events in IBD patients	26
DOP03 Unfermented β-fructan fibres can induce gut inflammation and tumorigenesis in select Inflammatory Bowel Disease patients mediated by gut microbiota	26
P367 Are patients with Inflammatory Bowel Disease and two or more associated Immune-Mediated Inflammatory Diseases different from those with no or one associated disease?	26
P162 The Biosimilar Switch: IBD nurse's experience in Our Lady of Lourdes Hospital	25
DOP56 Fibrosis-related transcriptome unveils a distinctive matrix remodelling pattern in penetrating but not in stricturing ileal Crohn's Disease	25
P747 Assessment of a microlearning programme for patients with Inflammatory Bowel Disease (The ADEII project) on ansiety/depression status and illness perception	25
P607 Increased rates of fractures and malignancy in elderly onset IBD in Singapore	25
P837 Improving Vaccination Rates in Patients with Inflammatory Bowel Disease: A Single Centre Audit and Quality Improvement Project	25
P250 Geriatric impairments associate with mortality and hospitalisations during follow-up in older IBD outpatients	25
P906 The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease. A retrospective observational study	24
P024 Synergistic effect of phytochemicals combination including ginsenosides and curcumin on recovery from radiation-induced toxicity	24
ECCO Grant Untangling the gut phagosome dynamics of the relapse/remission cycle in ulcerative colitis	24
P996 Clinical Efficacy and Predictive Factors for the Effectiveness of Granulocyte and Monocyte Adsorption Apheresis Therapy for Ulcerative Colitis：A Retrospective Observational Single Center Study	24
REACH: C—cause	23
P1079 Mindfulness-based cognitive therapy to reduce psychological distress in patients with Inflammatory Bowel Disease: first results of a multicentre randomised controlled trial (MindIBD)	23
Equitable access to inflammatory bowel disease care: challenges, strategies, and future directions	23
P1144 Forecasting the Future Prevalence of Inflammatory Bowel Disease in Korea through 2048: An Epidemiologic Study Employing Autoregressive Integrated Moving Average Models	23
P514 Beyond the First Attempt: A Multi-Centre UK Analysis of Second JAK Inhibitor Use in Ulcerative Colitis	23
P1237 Development of an algorithm to identify the best donor-recipient match for FMT in IBD patients based on immune system/microbiota interactions	23
P1104 Shifting Surgical Landscape in Crohn's Colitis: Laparoscopic Supremacy and Robotic Upsurge	23
OP14 Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis	22
P352 Occurrence of moderate to severe anaemia and utilization and efficacy of intravenous iron therapies in a nationwide cohort of Inflammatory Bowel Disease patients	22
DOP016 Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term Extension	22
DOP69 Longitudinal gut microbiome dynamics in relation to disease flares in Inflammatory Bowel Disease, pilot data from the IBD-Tracker study	22
Video Capsule Endoscopy can Identify Occult Luminal Crohn’s Disease in Patients with Isolated Perianal Fistulas	22
Incidence, Prevalence, Disease Course, and Treatment Strategy of Crohn’s Disease Patients from the Veszprem Cohort, Western Hungary: A Population-based Inception Cohort Study Between 2007 and 2018	22
Serum Metabolites Relate to Mucosal and Transmural Inflammation in Paediatric Crohn Disease	21
P060 Increased metabolic activity of faecal Sutterella Wadsworthensis at IBD onset is associated with an increased risk of escalation to biologic therapies - Results from the Birimingham Inception Coh	21
DOP23 The role of histology for the prediction of clinical relapse in Crohn’s Disease: A substudy of the STORI cohort	21
IBD Risk—It Is All in the Family!	21
Risk Prediction for Complications in Inflammatory Bowel Disease Surgery: External Validation of the American College of Surgeons’ National Surgical Quality Improvement Program Surgical Risk Calculator	21
OP17 The Tasty&Healthy whole food diet improves calprotectin in high risk first-degree relatives of patients with Crohn’s disease (FDRs): The PIONIR randomized controlled prevention cross-over tri	20
OP01 The Occupational Landscape of Inflammatory Bowel Disease Susceptibility and Modulating Roles of Pollutant Exposure, Work Behaviors, and Socioeconomic Status: A Multicohort Cross-Population Study	20
P1143 Effect of a Structured Yoga Module as an Adjunct to Standard Care in Mild–Moderate Ulcerative Colitis: A Prospective Observational Pilot of 15 Patients	20
P0852 UPARECOL-UC: Real-world effectiveness and safety of upadacitinib in ulcerative colitis in a Colombian cohort	20
DOP094 Machine Learning-Driven Raman Spectroscopy, Validated by Metabolomics, Identifies Novel Non-Invasive Biomarkers of Barrier Integrity and Outcomes in Inflammatory Bowel Disease	20
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies	20
P0217 Enhancing Patient Understanding of Perianal Fistula MRI Findings Using ChatGPT: A Real-World Evaluation	20
P0992 Assessment of the impact of telemonitoring on the psychological well-being of patients with Inflammatory Bowel Diseases	20
P1171 Endoscopic Treatment for Crohn’s Disease-related Deep Small Intestinal Strictures: Balloon-Assisted Enteroscopy-Guided Stricturotomy versus Balloon Dilation Therapy - A Single-Center Retrospecti	20
Increased Primary Bile Acids with Ileocolonic Resection Impact Ileal Inflammation and Gut Microbiota in Inflammatory Bowel Disease	20
DOP017 Unique serological signatures enable the diagnosis and stratification of Inflammatory Bowel Disease	20
P0213 A retrospective comparison of endoscopic ultrasonography and clinical parameters in assessing Ulcerative Colitis activity	20
DOP005 Mirikizumab treatment reduces Crohn’s disease-related surgery and hospitalization rates: analyses from VIVID-1	20
N09 Association between the clinical activity of Ulcerative Colitis and Inadequate protein intake: a cross-sectional study.	19
P0311 AI-assisted Intestinal Ultrasound - moving beyond static bowel wall thickness assessment towards a comprehensive full workflow solution	19
P0494 Unmasking IBS: a deep learning model for Functional Disease detection in patients with suspected ­Inflammatory Bowel Disease	19
N43 Comprehensive care for Inflammatory Bowel Disease: A coordinated case management approach between social work and nursing	19
P1269 Epidemiology and Clinical Features of Inflammatory Bowel Disease in Kuwait: A Multicenter (SEIF-IBD) Study	19
P1209 Early-life animal exposure does not influence the risk of inflammatory bowel disease	19
P1172 Incidence of Latent and Active Tuberculosis Among Indian IBD Patients on Biologic Therapy: A Single-Center Experience	19
P0328 A clinical decision support tool reliably predicts deep remission with vedolizumab for Crohn’s disease	19
P1257 Association between appendectomy and the risk of inflammatory bowel disease: results from an emulated target trial	19
P0536 Improved Surgical Outcomes but Persistent Readmission Burden After Ulcerative Colitis Flares: A 2010-2024 Cohort Analysis	19
P0142 S100A8/A9hi macrophage activates intestinal fibroblast via mCCL6/hCCL15-CCR1 axis to drive intestinal fibrosis in Crohn’s disease	19
P0175 Identifying Gene Signatures Underlying the Inflammation-to-Fibrosis Trajectory in Crohn’s Disease	18
Development of the Escalation of Therapy or Intervention (ETI) Calculator for Patients with Ulcerative Colitis Using ePROMs	18
DOP15 Intestinal ultrasound correlates with colonoscopy and biomarkers, and can be used in a tight monitoring approach to assess response to therapy in Crohn’s disease: a multicentre prospective study	18
P0356 A case of pulmonary nodules in Ulcerative Colitis and primary sclerosing cholangitis: is it drug or disease?	18
P1086 Splenic parenchymal stiffness measured by shear-wave elastography correlates with the activity of Inflammatory Bowel Disease	18
Restoring Prostacyclin/PGI2-PTGIR signaling alleviates intestinal fibrosis in Crohn’s disease via fibroblast-specific YAP/TAZ inhibition	18
P022 A correlation of serum Fibroblast Growth Factor 21 level with inflammatory markers and indicators of nutritional status in patients with Inflammatory Bowel Disease	18
P1020 Association of Post-Induction Ustekinumab levels with treatment response in inflammatory bowel disease patients	18
Clostridium perfringens: A Potential Pathobiont in Inflammatory Bowel Disease	18
P325 Proton pump inhibitors are associated with a disabling course of Crohn’s disease	18
DOP07 Targeting the canonical WNT signalling pathway as a potential novel therapy in Crohn′s associated fibrosis	18

OP28 Children and young adults with inflammatory bowel disease have an increased incidence and risk of developing mental health conditions: a UK population-based cohort study	17
P041 The upregulation of tissue factor in colonic mesenchymal cells in active ulcerative colitis is associated with severe and resistant to treatment disease, but tofacitinib has not effect on it	17
DOP68 Autophagy induction in the intestinal epithelium protects against inflammation-induced barrier loss in vivo.	17
P810 Association between Ustekinumab Trough Levels, Serum IL-22 and Oncostatin M Levels with Clinical and Biochemical Outcomes in Patients With Crohn’s Disease	17
N31 Nothing about us, without us: Developing a reliable IBD information source on sexual well-being by patients and for patients	17
P396 Ustekinumab Is A Promising Option For The Treatment Of Postoperative Recurrence Of Crohn’s Disease	17
P307 High frequency of Deep Infiltrating Endometriosis in patients with Inflammatory Bowel Disease: a nested case-control study	17
P103 Colitis-associated faecal miRNAs are mediators of host-microbiota interactions and key regulators of intestinal permeability and inflammation	17
P152 The prevalence of Thiopurine-methyltransferase and NUTD15 in patient with ulcerative colitis: a hospital-based study in central Taiwan	17
P524 Predictors of immunogenicity in patients with Inflammatory Bowel Disease treated with infliximab: A post hoc analysis of the randomised phase I CT-P13 SC study	17
P743 Relative association of bowel urgency improvement versus remission of stool frequency and rectal bleeding with Patient Global Rating of Severity or Change scores in moderately-to-severely active	17
P830 Significant racial and ethnic disparities exist in health-care utilization in inflammatory bowel disease: a systematic review and meta-analysis	17
DOP55 The increasing burden of direct and indirect costs of IBD	17
P329 Stool multiplex molecular PCR assay in comparison to conventional stool tests for detecting gastrointestinal infections as cause of flares in Inflammatory Bowel Disease	17
P569 Can thiopurines prevent crohn’s disease endoscopic postoperative recurrence in at risk patients?	17
P030 Assessing dietetic interventions in inflammatory bowel disease patients	17
P757 Visceral adiposity and not subcutaneous adiposity or body mass index is more strongly associated with relapse in inflammatory bowel disease	17
P607 HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel Disease	17
P649 Long-term follow-up of the PROTDILAT study; LONG-PROTDILAT Prospective multicenter randomized comparative study of endoscopic treatment of strictures in Crohn's disease (CD): self-expandable meta	16
P189 Lifestyle and psychosocial factors in IBD; prevalence and patients’ perspective	16
DOP27 Systemic antibody responses against gut microbiota flagellins implicate shared and divergent immune reactivity in Crohn's Disease and chronic fatigue syndrome	16
P865 Anxiety and Depression is Associated with Poor Sleep Quality in patients with Inflammatory Bowel Disease (IBD)	16
DOP41 Mucosal single-cell profiling of Crohn's-like disease of the pouch reveal unique pathogenesis and therapeutic targets	16
P1040 Comparative effectiveness of upadacitinib versus ustekinumab in patients with moderately to severely active Crohn’s disease: a matching-adjusted indirect comparison	16
P585 Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure	16
P235 Correlation of mental and psychological status to disease activity in patients with Inflammatory Bowel Disease using The Symptom Checklist -90- Revised Questionnaire (SCL90R)	16
P003 Metabolic Reprogramming in Intestinal Fibrosis: Integrating Metabolomics, Single-Cell Transcriptomics and Isotope Tracing	16
P319 Genetic polymorphism of lactose intolerance in patients with Inflammatory Bowel Disease	16
P592 Higher predictive power of epigenetic signatures for response to vedolizumab and ustekinumab in anti-TNF naïve patients with active Crohn’s disease	16
P867 Abdominally targeted yoga-based physical exercises as a therapeutic intervention for Inflammatory Bowel Diseases	16
P336 Exploring Extracellular Matrix Markers in Ulcerative Colitis: Degradation and Formation Insights	16
P119 Single-cell RNA sequencing in Inflammatory Bowel Disease in patients with Primary Sclerosing Cholangitis: a distinct form of colitis	16
P100 Salivary exosomes aggravate colitis via oral-gut axis	16
P084 Natural extracts and omega-3 derived molecule: role in resolution of intestinal inflammation	16
P349 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Descriptive Comparison of Experiences of Bowel Urgency among Patients with Ulcerative Colitis in Canada, Europe, and the US	16
P1020 Developing and Validating a Clinical Prediction Model Using Biomarkers to Assess Clinical Response and Severity of Crohn's Disease 12 Weeks After Initiation of Biological Therapy	16
P128 Salt-Inducible Kinase 2 is a promising therapeutic target in patients with ulcerative colitis	15
P738 Response to etrasimod treatment in ulcerative colitis is associated with a reduction of circulating B and pro-inflammatory T cells: a single-cell-based post-hoc sub-analysis of the ELEVATE UC 52	15
P940 A glance into paediatric Inflammatory Bowel Disease in Australasia – Crohn’s Colitis Cure (CCC) data insights program	15
P1218 Non-invasive point-of-care stool sample for detection of Cytomegalovirus infection in patients with Active or Refractory Ulcerative Colitis using multiplex polymerase chain reaction (mPCR): a pi	15
OP12 Therapeutic antibody clearance better predicts endoscopic outcomes than trough concentrations in patients with Crohn’s disease	15
P388 Eliakim score performance among patients with active Crohn’s disease	15
P1075 Outcomes in patients stopping biologic during the first trimester of pregnancy : a retrospective monocentric study	15
P1215 Blastocystis is very rare in faeces of children with Crohn’s disease: quantity, subtyping and association with the faecal bacteriome	15
P623 Network meta-analysis to evaluate the comparative efficacy of advanced therapies as first line for maintenance treatment of adult patients with moderate-to-severe Crohn’s disease	15
P526 Handsewn versus Stapled Ileocolic Anastomosis for Crohn's: Comparable Outcomes Despite More Severe Disease Profile in the Handsewn Group	15
P1137 Long-term trend of cumulative incidence of venous thromboembolism in Korean patients with inflammatory bowel disease: A nationwide population-based cohort study	15
P253 Histological Remission and Activity as Predictor of Relapse, Hospitalization, and Surgery in Ulcerative Colitis: Systematic Review and Meta-analysis	14
The ulcerative colitis risk gene adenylyl cyclase 7 restrains the T-helper 2 phenotype and Class II antigen presentation	14
P0513 Comparative Evaluation of Clinical Scores for Predicting Response to Systemic Steroid Treatment in Hospitalized Adult Patients with Acute Severe Ulcerative Colitis: A Retrospective Study	14
ECCO Grant Dissecting the intestinal mucosa-associated HUMoral immune response in ileal Crohn’s Disease: the HUM-CD study	14
P0106 Profiling inflammation-associated T helper subsets in Inflammatory Bowel Disease	14
N20 Transcutaneous Electrical Acupuncture-point Stimulation for Depressive symptoms in Inflammatory Bowel Disease: a feasibility study	14
P0671 Supporting vedolizumab treatment throughout pregnancy: Insights from a population pharmacokinetic model	14
P161 The use of Novel Natural Treatments for Inflammatory Bowel Diseases	14
Corrigendum: Darvadstrocel for Complex Perianal Fistulas in Japanese Adults with Crohn’s Disease: A Phase 3 Study	14
P874 Impact of immunogenicity on clinical outcomes in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study	14
P0395 Endoscopic Approaches for Colorectal Neoplasia Surveillance in Inflammatory Bowel Disease: A Systematic Review and Network Meta-Analysis	14
P0594 Efficacy and safety of etrasimod in Japanese UC patients: results of a phase 2 dose-ranging study	14
P0599 Efficacy and safety of intravenous methylprednisolone and hydrocortisone in Acute Severe Ulcerative Colitis (ASUC) – a posthoc analysis of the IASO trial	14
P0590 Long term outcomes of biologic therapy for the treatment of prepouch ileitis: a multi-centre multi-national retrospective study	14
Development and validation of a novel multimodal deep learning model integrating histopathology, radiology, and clinical data to predict primary non-response to infliximab in patients with Crohn’s dis	14
P012 Intestinal epithelial cells as targets of thiopurines in Inflammatory Bowel Disease paediatric patients-derived organoids	14
P963 The comparative effectiveness and safety of different biologics in young (<60 years) versus elderly (≥60 years) patients with IBD: results from a real-world experience at a Belgian tertiar	14
P0142 CD47-SIRPα Contributes to the Microenvironment of Stricturing Crohn's Disease by Mediating the Crosstalk between Macrophages and Stromal cells: “Eat Me” or “Don't Eat Me”	14
P0575 Bronchiectasis in patients with inflammatory bowel disease – prevalence, predictors, and clinical characteristics	14
P1270 Drugs associated with Microscopic Colitis: a comprehensive pharmacovigilance analysis	14
P0432 CMV infection in IBD patients with disease flare in the era of advanced therapies and outpatient setting	14
P0466 Impact of the COVID-19 Pandemic on Clinical Presentation and Management of Inflammatory Bowel Disease: A Multicentre Study in the West Midlands, UK	13
P0544 Long-term evaluation of quality of life in inflammatory bowel diseases: results from a prospective cohort study	13
P0798 Forty-eight months outcomes of Teduglutide in adult stable patients with short bowel syndrome and home parental nutrition dependence: a real-world italian single center observational cohort stud	13
Self-care in patients affected with inflammatory bowel disease and Mutuality in nursing: A protocol for a longitudinal study	13
P0447 Accurate, rapid and economical diagnosis of chronic enteropathy associated with SLCO2A1 gene and the analysis of its clinical pathological features	13
P0368 Novel endoluminal parameters to predict primary loss of response in patients with Crohn’s disease: a national survey and multi-centre study	13
P1240 Overweight in patients with inflammatory bowel disease and the associated risk of malnutrition	13
P1255 Impact of depression on health related quality of life in Ulcerative Colitis patients-are we doing enough? A single tertiary center experience	13
P0048 Alterations in circulating T-cell subpopulations reflect disease activity in Ulcerative Colitis	13
P0280 Evaluation of the diagnostic accuracy of trans-perineal ultrasound for predicting rectal histoendoscopic remission in Ulcerative Colitis (The TRINITY Study): A prospective, paired, comparative s	13
P0211 Characterization of drug-specific CD4+ T cells in patients with inflammatory bowel diseases	13
P1219 Late onset inflammatory bowel disease (IBD): Experience from two tertiary centers in Greece	13
P1167 Treatable traits (TTs) approach in the management of Inflammatory Bowel Disease: a new concept	13
P125 MIG (CXCL9) and IL22 are key biomarkers that discriminates between paediatric IBD patients and non-IBD patients in a novel biomarker model	12
DOP055 Efficacy and Safety Up to 3 Years of Risankizumab Maintenance Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Results from Phase 3 COMMAND Open-Label Extens	12
P1090 Drug retention in Vedolizumab-treated patients with active UC after the addition of adjunct curcumin-QingDai: An interim analysis of a retrospective real-world cohort study	12
Crohn’s disease is an obstructive lymphangitis	12
P0515 Development and validation of a multimodal prediction model for endoscopic activity in Crohn’s disease	12
A Protective Role of NOD2 on Oxazolone-induced Intestinal Inflammation Through IL-1β-mediated Signalling Pathway	12
P507 United States and European patient perspectives on the impact of moderate-to-severe Ulcerative Colitis on sexual activity: Communicating Needs and Features of IBD Experiences (CONFIDE) survey	12
P1096 Randomised controlled trial of continued intravenous versus switching to subcutaneous infliximab in inflammatory bowel disease: the Subcutaneous Infliximab Switch Study (SISS).	12
P1104 The Crohn’s Disease Exclusion Diet with Early Dairy Introduction Study (CD-EDEN)	12
P1159 Pooled analysis of efficacy and safety of once-daily oral obefazimod in European patients from the ABTECT Phase 3, double-blind, placebo-controlled induction trials	12
Automated real-time imaging of intestinal barrier integrity and molecular profiling for early outcome prediction in inflammatory bowel disease: endo-histo-barrier-omics study	12
P1298 Patient-reported lower urinary tract symptoms in Inflammatory Bowel Disease versus controls: results from the plutino study	12
P0704 Optimizing malnutrition risk detection in Inflammatory Bowel Disease: a longitudinal analysis of serial nutritional screening tools	12
P1246 Evolution of epidemiological stages of ulcerative colitis in Hungary – trends of age and gender specific incidence and prevalence from a population-based cohort between 1977–2018	12